Abstract

The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical trials based on cell engineering and adoptive cell therapies.
Its aims are as follows:
AIM1 : To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2 : GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks (plasmid DNA, cell banks).
AIM3 : Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability); Gene transfer/expression.
AIM4 : To monitor patients? samples post-infusion (e.g., FACS, Q-PCR).
AIM5 : To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084821
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Hsin, Jing-Ping; Lu, Yuheng; Loeb, Gabriel B et al. (2018) The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol 19:1137-1145
Senders, Max L; Hernot, Sophie; Carlucci, Giuseppe et al. (2018) Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC Cardiovasc Imaging :
Rogers, Emma M; Connolly, Karen L; Nehal, Kishwer S et al. (2018) Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer. J Am Acad Dermatol 78:1119-1124
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Gay, Hiram A; Oh, Jung Hun; Apte, Aditya P et al. (2018) Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer. Clin Transl Radiat Oncol 13:1-6
Touijer, Karim A; Karnes, Robert Jeffery; Passoni, Niccolo et al. (2018) Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 73:890-896
Pianko, Matthew J; Moskowitz, Alison J; Lesokhin, Alexander M (2018) Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 24:1002-1010
Bucciarelli, Peter R; Tan, Kay See; Chudgar, Neel P et al. (2018) BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol 13:73-84
Yang, Annie; Baxi, Shrujal; Korenstein, Deborah (2018) ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. J Oncol Pract 14:72-76
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276

Showing the most recent 10 out of 8799 publications